anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Among the individual of investigated the cohort, seven patients underwent groin revision for subsequent hydrocele, 4 for recurrence, and 4 for overlooked ipsilateral multiple hernia protrusions. Made from low weight, large porous polypropylene, ProFlor is composed of a multilamellar cylindrical 3D core, 15 mm thick, with 2 different longitudinal dimensions, 25 or 40 mm. The center of the implant core is connected on one surface to a flat mesh of different width depending on the dimension of the 3D core. This flat part of the device is intended to be deployed to counterface the peritoneal sheath. The 3D core of ProFlor ® is arranged to be compressible on both planes, longitudinal and transversal. Due to its proprietary centrifugal expansion, it can be positioned, fixation free, into the hernia defect for permanent obliteration. ProFlor owns an inherent dynamic responsivity as it contracts and relaxes in accord to the movements of the inguinal floor in which is positioned.

The biopsies were excised from the anterior aspect of the 3D device. It should be noted that once deployed the anterior surface of ProFlor merely faces the external oblique fascia and has no contact with other structures of the groin. Therefore, corruption by host native tissue can be excluded. The biopsies were carried out in ten patients, three in the short term postop. between 3 and 5 weeks, five in the mid-term between 3 and 4 months postop., four in the long-term between 6 and 8 months postop. and the latter three in the extra-long term postop., more than three years after implantation.
PURPOSE:To obtain a remedy for allergic diseases having inhibitory action of anaphylaxis shock and Arthus reaction and action of increasing the intracutaneous reaction threshold value from a substance obtained from urine of a patient with allergic disease. CONSTITUTION:Zinc chloride is added to urine of a patient with an allergic disease to form precipitates, which are then collected and added to an aqueous solution of sodium primary phosphate to collect the supernatant liquid. Methanol, etc., is then added to the resultant supernatant liquid to deposit precipitates, which are then dissolved in water to give an aqueous solution. The aqueous solution is then subjected to gel filtration to collect a fraction containing phosphoric acid ions. A bi- or trivalent metal chloride is then added to the above- mentioned fraction to collect the supernatant liquid and further NaOH is added to neutralize chlorine ions. The supernatant liquid is collected and subjected to gel filtration to collect a fraction eluted before the fraction containing NaCl and obtain the aimed substance having inhibitory action on anaphylaxis shock.
PURPOSE: To obtain a pharmaceutical preparation capable of selectively and surely releasing a pharmacodynamically effective ingredient in the colon with good reproducibility by coating a composition containing the pharmacodynamically effective ingredient with a base containing a polymeric substance, having a specific intrinsic viscosity and decomposable in the colon. CONSTITUTION: This pharmaceutical preparation is obtained by coating a composition containing a pharmacodynamically effective ingredient with a base, having 0.2-2dl/g intrinsic viscosity and decomposable in the colon to preferably 10-200μm thickness. For example, a copolymer comprising structural units of formulas I and II [R is a bivalent organic group; R<1> is a saccharide residue decomposed or assimilated in the colon; X<1> and X<2> are each O, S, etc.; R<2> is a polyalkylene, a polyamide, etc.] is cited as the polymeric substance decomposable in the colon. A copolymer in which a dibasic acid constituting the units I and II is terephthalic or isophthalic acid, a saccharide constituting the unit I is cellobiose and a polyalkylene glycol constituting the unit II is polytetramethylene glycol or polypropylene glycol is preferred as the copolymer.
After taking of the blood samples, patients in Group I will be intubated with 0.3 mg/kg etomidate iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
Chronic oral toxicity studies in mice (up to 32 mg/kg/day; 96 mg/m2/day) did not indicate a carcinogenic potential for ketoprofen. The maximum recommended human therapeutic dose is 300 mg/day for a 60 kg patient with a body surface area of 1.6 m2, which is 5 mg/kg/day or 185 mg/m2/day. Thus, the mice were treated at 0.5 times the maximum human daily dose based on surface area.

A 2 year carcinogenicity study in rats, using doses up to 6 mg/kg/day (36 mg/m2/day), showed no evidence of tumorigenic potential. All groups were treated for 104 weeks except the females receiving 6 mg/kg/day (36 mg/m2/day) where the drug treatment was terminated in week 81 because of low survival; the remaining rats were sacrificed after week 87. Their survival in the groups treated for 104 weeks was within 6% of the control group. An earlier 2 year study with doses up to 12.5 mg/kg/day (75 mg/m2/day) also showed no evidence of tumorigenicity, but the survival rate was low and the study was therefore judged inconclusive. Ketoprofen did not show mutagenic potential in the Ames Test. Ketoprofen administered to male rats (up to 9 mg/kg/day; or 54 mg/m2/day) had no significant effect on reproductive performance or fertility. In female rats administered 6 or 9 mg/kg/day (36 or 54 mg/m2/day), a decrease in the number of implantation sites has been noted. The dosages of 36 mg/m2/day in rats represent 0.2 times the maximum recommended human dose of 185 mg/m2/day (see above).

Abnormal spermatogenesis or inhibition of spermatogenesis developed in rats and dogs at high doses, and a decrease in the weight of the testes occurred in dogs and baboons at high doses.
In the first stage, an information form including socio-demographic characteristics prepared within the framework of the literature and State-Trait Anxiety Inventory will be applied to mothers before surgery. Later, the experimental group will be knitted by the researcher during the surgical operation. The necessary materials (knitting needle and thread) for the knitting attempt will be given to the participants in the experimental group by the researcher. A neutral color, white, will be used as the knitting yarn color. Knitting will start 15 minutes after the child enters the operation and will be knitted for 30-40 minutes on average. At the end of the surgery, the State-Trait Anxiety Inventory scale will be applied again to evaluate the anxiety levels of the participants in the experimental and control groups. The vital signs of the mothers will be measured at the beginning of the operation and close to the end of the operation.
Fatal and life-threatening immune-mediated complications have been reported in recipients of POTELIGEO. Grade 3 or higher immune-mediated or possibly immune-mediated reactions have included myositis, myocarditis, polymyositis, hepatitis, pneumonitis, glomerulonephritis and a variant of Guillain-Barré syndrome. Use of systemic immunosuppressants for immune-mediated reactions was reported in 1.9% (6/319) of recipients of POTELIGEO in Trial 1, including for a case of Grade 2 polymyalgia rheumatica. New-onset hypothyroidism (Grade 1 or 2) was reported in 1.3% of patients and managed with observation or levothyroxine. Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.
FIELD: chemistry, biochemistry, immunochemistry. SUBSTANCE: method involves treatment of polysaccharide from duck's-meat Lemna minor with a trifluoroacetic acid solution in concentration 0.01-0.02 mole/l at temperature 70-100 C for 1-4 h, precipitation of polysaccharide from solution with 96% ethyl alcohol and removal of precipitated deposit by centrifugation. The end product is isolated by concentration, supernatant drying by evaporation with methanol under vacuum at temperature 40 C. Treatment of polysaccharide with a trifluoroacetic acid solution is carried out in the ratio of mass of the parent polysaccharide and a solvent volume = (1-3) : (100-400). The precipitation of polysaccharide from a solution with ethyl alcohol is carried out in the ratio solution : alcohol = 1: (3-4), respectively. Method ensures to isolate D-apiose in an individual state with a specific rotation value [α]       20   D       +5,4 °  (c. = 1.0; H 2 O) as a syrup-like form. The isolated apiose is a valuable biochemical preparation used in the investigation of chemical structure, biochemical behavior of different physiologically active compounds, for assay of determinant groups of immunomodulating agents. EFFECT: improved method of preparing, valuable properties of apiose. 3 cl, 1 tbl, 2 ex
The invention provides a height-increasing traditional Chinese medicine for female. The medicine comprises the raw materials in parts by weight: 2-15 parts of Sambucus chinensis, 2-20 parts of pseudo-ginseng, 10-30 parts of Codonopsis pilosula, 2-15 parts of ceris chinensis, 1-10 parts of flowers carthami, 2-20 parts of Cordyceps sinensis, 2-30 parts of Platycodon grandiflorum, 1-10 parts of stephania sinica diels, 2-10 parts of basil, 2-10 parts of old ginger, 20-30 parts of water, 20-30 parts of spirit, 2-15 parts of hen meat and 2-10 parts of sesame oil. With the adoption of height-increasing traditional Chinese medicine method, the height-increasing traditional Chinese medicine for female is internationally accepted effective height-increasing path. The method has the advantages of safety, scarce complications and no operation. The method is simple, less in pain and low in expense. Furthermore, the effective rate reaches over 96%.
New chelators such as H 3 L1, H 3 L2, H 3 L3, H 3 L26 and derivatives were synthesized for the complexation of {Al 18 F} 2+ . These new chelators are able to complex {AI 18 F} 2+  with good radiochemical yields using a labeling temperature of 37° C. The stability of the new Al 18 F-complexes was tested in phosphate buffered saline (PBS) at pH 7 and in rat serum. AI 18 F-L3 and AI 18 F-L26 showed a stability comparable to that of the previously reported Al 18 F-NODA. Moreover, the biodistribution of Al 18 F-L3 and AI 18 F-L26 showed absence of in vivo demetallation since only very limited bone uptake was observed, whereas the major fraction of activity 60 min p.i. was observed in liver and intestine due to hepatobiliary clearance of the radiolabeled ligand. The chelators H 3 L3 and Al 18 F-L26 demonstrated to be a good lead candidates for the labeling of heat sensitive biomolecules with  18 F-fluorine and derivatives have been synthesized. We have explored the complexation of {AI 18 F} 2+  with new chelators and obtained very favourable radiochemical yields (>85%) using a labeling temperature of 37° C. The stability of the new Al 18 F-complexes was tested in phosphate buffered saline (PBS) at pH 7 and in rat serum at 37° C., where AI 18 F-L3 and AI 18 F-L26 showed a stability comparable to that of the previously reported Al 18 F-NODA. Moreover, the biodistribution of Al 18 F-L3 and Al 18 F-L26 showed high stability, since only very limited bone uptake—which would be an indication of release of fluorine-18 in the form of fluoride—was observed, whereas the major fraction of activity 60 min p.i. was observed in liver and intestines due to hepatobiliary clearance of the radiolabeled ligand. The chelators H 3 L3 and H 3 L26 demonstrated to be good lead candidates for the labeling of heat sensitive biomolecules with  18 F-fluorine and several derivatives have been synthesized.
Provided is a thin patch having a flexible patch body, an outer layer, and a release layer. The flexible patch body has a waterproof and moisture-permeable layer and an adhesive gel layer. The outer layer is attached on the waterproof and moisture-permeable layer. The outer layer has a left wrapper and a right wrapper which are adjacent to each other. The release layer includes a first release film and a second release film. The first release film includes a release part attached on a side of the adhesive gel layer and a connecting part extending from the release part of the first release film and folded away from the adhesive gel layer. The second release film is attached on a part of the adhesive gel layer and covers a part of the connecting part of the first release film.
Conservative treatment will be performed within N h, where N = 72 h minus duration of acute intestinal obstruction. Surgery will be performed in the absence of contrast in colon according to X-ray examination and if signs of clinical degradation will appear.
Voriconazole was compared to the regimen of amphotericin B followed by fluconazole in Study 608, an open-label, comparative study in nonneutropenic patients with candidemia associated with clinical signs of infection. Patients were randomized in 2:1 ratio to receive either voriconazole (n=283) or the regimen of amphotericin B followed by fluconazole (n=139). Patients were treated with randomized study drug for a median of 15 days. Most of the candidemia in patients evaluated for efficacy was caused by C. albicans (46%), followed by C. tropicalis (19%), C. parapsilosis (17%), C. glabrata (15%), and C. krusei (1%). 

An independent Data Review Committee (DRC), blinded to study treatment, reviewed the clinical and mycological data from this study, and generated one assessment of response for each patient. A successful response required all of the following: resolution or improvement in all clinical signs and symptoms of infection, blood cultures negative for Candida, infected deep tissue sites negative for Candida or resolution of all local signs of infection, and no systemic antifungal therapy other than study drug. The primary analysis, which counted DRC-assessed successes at the fixed time point (12 weeks after End of Therapy [EOT]), demonstrated that voriconazole was comparable to the regimen of amphotericin B followed by fluconazole (response rates of 41% and 41%, respectively) in the treatment of candidemia. Patients who did not have a 12-week assessment for any reason were considered a treatment failure. 

The overall clinical and mycological success rates by Candida species in Study 150-608 are presented in Table 15. 

In a secondary analysis, which counted DRC-assessed successes at any time point (EOT, or 2, 6, or 12 weeks after EOT), the response rates were 65% for voriconazole and 71% for the regimen of amphotericin B followed by fluconazole. 

In Studies 608 and 309/604 (non-comparative study in patients with invasive fungal infections who were refractory to, or intolerant of, other antifungal agents), voriconazole was evaluated in 35 patients with deep tissue Candida infections. A favorable response was seen in 4 of 7 patients with intra-abdominal infections, 5 of 6 patients with kidney and bladder wall infections, 3 of 3 patients with deep tissue abscess or wound infection, 1 of 2 patients with pneumonia/pleural space infections, 2 of 4 patients with skin lesions, 1 of 1 patients with mixed intra-abdominal and pulmonary infection, 1 of 2 patients with suppurative phlebitis, 1 of 3 patients with hepatosplenic infection, 1 of 5 patients with osteomyelitis, 0 of 1 with liver infection, and 0 of 1 with cervical lymph node infection.
BACKGROUND: This systematic review investigated the prevalence of orofacial pain in patients with mild cognitive impairment (MCI) or dementia.
MATERIALS AND METHODS: The search was conducted in five databases (Medline (Ovid), Embase (Ovid), CINAHL, Scopus and LILACS), in three grey literature sources and in included articles' reference lists. Three independent reviewers performed study selection, quality appraisal and data extraction. The risk of bias was assessed with the National Institutes of Health tool. Prevalence was calculated using the random-effects model. Subgroup analysis and meta-regression were used to explore the heterogeneity of results.
RESULTS: The database and grey literature search led to 12 246 results, from which nine studies were included; a further four were selected through citation searching. The total sample comprised 6115 patients with dementia and 84 with MCI. All studies had high risk of bias. The overall estimated pooled prevalence of orofacial pain among dementia participants was 19.0% (95% CI, 11.0%-27.0%; I 2, 97.1%, P < .001). Only one study included MCI participants, among which the prevalence of orofacial pain was 20.5%. Subgroup analysis demonstrated that the different sources of diagnosis might explain the heterogeneity. A higher prevalence of orofacial pain was observed in dementia participants aged over 80 years or living in nursing homes. Meta-regression analysis showed a nonlinear relationship between age and the prevalence of orofacial pain.
CONCLUSIONS: The pooled data from the primary studies revealed that 2 out of 10 patients with dementia have orofacial pain. Further research is needed to clarify the magnitude in individuals with MCI.
Insulin to be administered by the mouth is protected against destruction of the juices of the stomach and intestines by admixture with one or more organic dyestuffs.  Protection against pepsin is obtained by the use of acid dyestuffs such as trypan red, Congo red, indigo carmine, and methyl orange.  Substances promoting resorption, such as saponins, may also be added.  The Specification as open to inspection under Sect. 91 refers also to the use of dyestuffs of the disazo, benzidine, indigo, triphenylmethane, acid monazo, and phthalein groups, and in particular of water blue, Bordeaux red, eosin BA and a mixture of trypan red, as an acid dyestuff, with malachite green, as a basic dyestuff; it refers also to the addition of anti-fermentative agents such as alcoholic solutions, and of inert fillers such as secondary calcium phosphate.  This subject-matter does not appear in the Specification as accepted.
The intestinal microbiota represents a key element in maintaining the homeostasis and health conditions of the host. Vascular pathologies and other risk factors such as aging have been recently associated with dysbiosis. The qualitative and quantitative alteration of the intestinal microbiota hinders correct metabolic homeostasis, causing structural and functional changes of the intestinal wall itself. Impairment of the intestinal microbiota, combined with the reduction of the barrier function, worsen the pathological scenarios of peripheral tissues over time, including the vascular one. Several experimental evidence, collected in this review, describes in detail the changes of the intestinal microbiota in dysbiosis associated with vascular alterations, such as atherosclerosis, hypertension, and endothelial dysfunction, the resulting metabolic disorders and how these can impact on vascular health. In this context, the gut-vascular axis is considered, for the first time, as a merged unit involved in the development and progression of vascular pathologies and as a promising target. Current approaches for the management of dysbiosis such as probiotics, prebiotics and dietary modifications act mainly on the intestinal district. Postbiotics, described as preparation of inanimate microorganisms and/or their components that confers health benefits on the host, represent an innovative strategy for a dual management of intestinal dysbiosis and vascular pathologies. In this context, this review has the further purpose of defining the positive effects of the supplementation of bacterial strains metabolites (short‑chain fatty acids, exopolysaccharides, lipoteichoic acids, gallic acid, and protocatechuic acid) restoring intestinal homeostasis and acting directly on the vascular district through the gut-vascular axis.
The present invention is directed toward vector stage replication-defective flaviviruses that are replication-defective in mosquito vectors that transmit them to humans. Such mutant flaviviruses may be useful as vaccines. The replication-defective flaviviruses of the present invention demonstrate a limited ability to replicate in the vector organisms that transmit flaviviruses from one host to another. More specifically, the present invention is directed toward the construction and propagation of flaviviruses that possess 3'-noncoding regions altered in such a way as to prevent or severely limit viral reproduction in a vector organism. In one embodiment of the present invention, a replication-defective dengue virus that is replication-defective in arthropods is contemplated for use as a vaccine. In another embodiment, a replication-defective dengue virus that is replication-defective in mosquitoes is contemplated for use as a vaccine. The present invention also contemplates methods of producing such mutant flaviviruses for use as vaccines as well as methods that induce a protective immunity against flavivirus infection or disease in an immunized subject.
Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. 

Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active.
Subjects will receive FOLFIRINOX as an outpatient every 14 days per community standards of medical care. Protocol-based therapy will continue for 12 cycles (24 weeks) or until disease progression, unacceptable toxicity, study withdrawal, or subject death. Subjects will have the option of surgical resection after 8 cycles of therapy if repeat scans show evidence of resectable disease. The starting doses for mFOLFIRINOX regimen are: oxaliplatin 85 mg/m2, followed by leucovorin 400 mg/m2 given simultaneously with irinotecan 180mg/m2, followed by 5FU 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion.